Targeting PSMA by radioligands in non-prostate disease—current status and future perspectives

  • Philipp Backhaus
  • Benjamin Noto
  • Nemanja Avramovic
  • Lena Sophie Grubert
  • Sebastian Huss
  • Martin Bögemann
  • Lars Stegger
  • Matthias Weckesser
  • Michael Schäfers
  • Kambiz Rahbar
Review Article

Abstract

Background

Prostate-specific membrane antigen (PSMA) is the up-and-coming target for molecular imaging of prostate cancer. Despite its name, non-prostate-related PSMA expression in physiologic tissue as well as in benign and malignant disease has been reported in various publications. Unlike in prostate cancer, PSMA expression is only rarely observed in non-prostate tumor cells. Instead, expression occurs in endothelial cells of tumor-associated neovasculature, although no endothelial expression is observed under physiologic conditions. The resulting potential for tumor staging in non-prostate malignant tumors has been demonstrated in first patient studies. This review summarizes the first clinical studies and deduces future perspectives in staging, molecular characterization, and PSMA-targeted radionuclide therapy based on histopathologic examinations of PSMA expression.

Conclusions

The non-exclusivity of PSMA in prostate cancer opens a window to utilize the spectrum of available radioactive PSMA ligands for imaging and molecular characterization and maybe even therapy of non-prostate disease.

Keywords

Prostate cancer PSMA Prostate-specific membrane antigen Endothelium PET/CT Angiogenesis 

Notes

Acknowledgements

P.B. is supported by a clinician-scientist position through DFG SFB 1009 “Breaking Barriers”, Münster, Germany.

Compliance with ethical standards

Disclosure

The University of Münster received consulting fees from ABX Advanced Biochemical Compounds, Radeberg, Germany for KR, MB. The authors declare that they have no conflict of interest according to the subject and matter of the presented article.

Conflict of interest

The authors declare that they have no financial or non-financial competing interests.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.

References

  1. 1.
    Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res [Internet]. 1997;3:81–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9815541.Google Scholar
  2. 2.
    Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate-specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer [Internet]. 1998;82:2256–61. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9610707.CrossRefGoogle Scholar
  3. 3.
    Eder M, Schäfer M, Bauder-Wüst U, Hull WE, Wängler C, Mier W, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem [Internet]. 2012;23:688–97. Available from: http://pubs.acs.org/doi/abs/10.1021/bc200279b.CrossRefGoogle Scholar
  4. 4.
    Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486–95.PubMedCrossRefGoogle Scholar
  5. 5.
    Maurer T, Eiber M, Schwaiger M, Gschwend JE. Current use of PSMA–PET in prostate cancer management. Nat. Rev. Urol. [Internet]. Nature Publishing Group; 2016;13:1–10. Available from: http://www.nature.com/doifinder/10.1038/nrurol.2016.26.
  6. 6.
    Benešová M, Schäfer M, Bauder-Wüst U, Afshar-Oromieh A, Kratochwil C, Mier W, et al. Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med. 2015;56:914–20.PubMedCrossRefGoogle Scholar
  7. 7.
    Chen Y, Pullambhatla M, Foss CA, Byun Y, Nimmagadda S, Senthamizhchelvan S, et al. 2-(3-{1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res. 2011;17:7645–53.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Cardinale J, Schäfer M, Benešová M, Bauder-Wüst U, Leotta K, Eder M, et al. Preclinical evaluation of [18F]PSMA-1007: a new PSMA-ligand for prostate cancer imaging. J Nucl Med [Internet]. 2016;181768:1–27. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27789722.Google Scholar
  9. 9.
    Dietlein M, Kobe C, Kuhnert G, Stockter S, Fischer T, Schomäcker K, et al. Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer. Mol Imaging Biol. 2015;17:575–84.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Giesel FL, Kesch C, Yun M, Cardinale J, Haberkorn U, Kopka K, et al. 18F–PSMA-1007 PET/CT detects micrometastases in a patient with biochemically recurrent prostate cancer. Clin Genitourin Cancer [Internet] Elsevier Inc; 2017;15:e497–e499. Available from:  https://doi.org/10.1016/j.clgc.2016.12.029.
  11. 11.
    Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44:678–88.PubMedCrossRefGoogle Scholar
  12. 12.
    Goffin KE, Joniau S, Tenke P, Slawin K, Klein EA, Stambler N, et al. Phase 2 study of 99m Tc-trofolastat SPECT/CT to identify and localize prostate cancer in intermediate- and high-risk patients undergoing radical prostatectomy and extended pelvic lymph node dissection. J Nucl Med [Internet]. 2017; Available from: http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.116.187807.
  13. 13.
    Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, et al. The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;42:197–209.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Eiber M, Maurer T, Souvatzoglou M, Beer A, Ruffani A, Haller B, et al. Evaluation of hybrid 68Ga-PSMA-ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med [Internet]. 2015;56:668–74. Available from: http://jnm.snmjournals.org/cgi/doi/10.2967/jnumed.115.154153.CrossRefGoogle Scholar
  15. 15.
    Afshar-Oromieh A, Holland-Letz T, Giesel FL, Kratochwil C, Mier W, Haufe S, et al. Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging. 2017;44:1258–68.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G, et al. Diagnostic efficacy of 68Gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high-risk prostate cancer. J Urol [Internet]. 2016;195:1436–43. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0022534715053975.CrossRefGoogle Scholar
  17. 17.
    Pyka T, Okamoto S, Dahlbender M, Tauber R, Retz M, Heck M, et al. Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer. Eur J Nucl Med Mol Imaging [Internet]. 2016;43:2114–21. Available from: http://dx.doi.org/10.1007/s00259-016-3435-0.CrossRefGoogle Scholar
  18. 18.
    Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, et al. Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41:11–20.PubMedCrossRefGoogle Scholar
  19. 19.
    Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, Ho B, Nguyen Q, et al. Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med [Internet]. 2015;56:1185–90. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26112024.CrossRefGoogle Scholar
  20. 20.
    Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res [Internet]. 1987;7:927–35. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2449118.Google Scholar
  21. 21.
    Bařinka C, Rojas C, Slusher B, Pomper M. Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer. Curr Med Chem [Internet]. 2012;19:856–70. Available from: https://www.ncbi.nlm.nih.gov/pubmed/22214450.
  22. 22.
    Kinoshita Y, Kuratsukuri K, Landas S, Imaida K, Rovito PM, Wang CY, et al. Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg. 2006;30:628–36.PubMedCrossRefGoogle Scholar
  23. 23.
    Kirchner J, Schaarschmidt BM, Sawicki LM, Heusch P, Hautzel H, Ermert J, et al. Evaluation of practical interpretation hurdles in 68Ga-PSMA PET/CT in 55 patients: physiological tracer distribution and incidental tracer uptake. Clin Nucl Med [Internet]. 2017;42:322–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28481787.CrossRefGoogle Scholar
  24. 24.
    Rahbar K, Vehren T, Boegemann M, Breyholz H-J, Schaefers M, Weckesser M. Dual time point PET/CT acquisition using Ga-68-PSMA-radioligand. J. Nucl. Med. [Internet]. Society of Nuclear Medicine; 2015 [cited 2017 Aug 31]. p. 1437–1437. Available from: http://jnm.snmjournals.org/cgi/content/short/56/supplement_3/1437.
  25. 25.
    Freitag MT, Radtke JP, Afshar-Oromieh A, Roethke MC, Hadaschik BA, Gleave M, et al. Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI. Eur J Nucl Med Mol Imaging. 2017;44:776–87.PubMedCrossRefGoogle Scholar
  26. 26.
    Sheikhbahaei S, Afshar-Oromieh A, Eiber M, Solnes LB, Javadi MS, Ross AE, et al. Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. Eur J Nucl Med Mol Imaging [Internet]. 2017:1–20. Available from: http://link.springer.com/10.1007/s00259-017-3780-7.
  27. 27.
    Chang SS, Reuter VE, Heston WDW, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 1999;59:3192–8.PubMedGoogle Scholar
  28. 28.
    Crowley MJP, Scognamiglio T, Liu YF, Kleiman DA, Beninato T, Aronova A, et al. Prostate-specific membrane antigen is a potential antiangiogenic target in adrenocortical carcinoma. J Clin Endocrinol Metab. 2016;101:981–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Law WP, Fiumara F, Fong W, Miles KA. Gallium-68 PSMA uptake in adrenal adenoma. J Med Imaging Radiat Oncol. 2016;60:514–7.PubMedCrossRefGoogle Scholar
  30. 30.
    Peper JGK, Srbljin S, van der Zant FM, Knol RJJ, Wondergem M. High 18Fluor-DCFPyL uptake in adrenal adenomas. Clin. Nucl. Med. [Internet]. 2017;0:1. Available from: http://insights.ovid.com/crossref?an=00003072-900000000-97923.
  31. 31.
    Sasikumar A, Joy A, Pillai MRA, Alex TM, Narayanan G. 68Ga-PSMA PET/CT in osteosarcoma in fibrous dysplasia. Clin Nucl Med. 2017;42:1.CrossRefGoogle Scholar
  32. 32.
    Zeng C, Ke Z-F, Yang Z, Wang Z, Yang S-C, Luo C-Q, et al. Prostate-specific membrane antigen: a new potential prognostic marker of osteosarcoma. Med Oncol [Internet]. 2012;29:2234–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22009216.CrossRefGoogle Scholar
  33. 33.
    Heitkötter B, Trautmann M, Grünewald I, Bögemann M, Rahbar K, Gevensleben H, et al. Expression of PSMA in tumor neovasculature of high grade sarcomas including synovial sarcoma, rhabdomyosarcoma, undifferentiated sarcoma and MPNST. Oncotarget [Internet]. 2017;8:4268–76. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354830/.
  34. 34.
    Artigas C, Alexiou J, Garcia C, Wimana Z, Otte FX, Gil T, et al. Paget bone disease demonstrated on 68Ga-PSMA ligand PET/CT. Eur J Nucl Med Mol Imaging. 2016;43:195–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Blazak JK, Thomas P. Paget disease: a potential pitfall in PSMA PET for prostate cancer. Clin. Nucl. Med. [Internet]. Elsevier Saunders; 2016;41:699–700. Available from: http://emedicine.medscape.com/article/334607.
  36. 36.
    Bourgeois S, Gykiere P, Goethals L, Everaert H, De Geeter FW. Aspecific uptake of 68GA-PSMA in Paget disease of the bone. Clin Nucl Med [Internet]. 2016;41:877–8. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00003072-201611000-00010.CrossRefGoogle Scholar
  37. 37.
    Derlin T, Weiberg D, Sohns JM. Multitracer molecular imaging of Paget disease targeting bone remodeling, fatty acid metabolism, and PSMA expression on PET/CT. Clin Nucl Med. 2016;41:991–2.PubMedCrossRefGoogle Scholar
  38. 38.
    Froehner M, Toma M, Zöphel K, Novotny V, Laniado M, Wirth MP. PSMA-PET/CT-positive Paget disease in a patient with newly diagnosed prostate cancer: imaging and bone biopsy findings. Case Rep Urol [Internet]. 2017;2017:1–3. Available from: https://www.hindawi.com/journals/criu/2017/1654231/.
  39. 39.
    Rowe SP, Deville C, Paller C, Cho SY, Fishman EK, Pomper MG, et al. Uptake of (18)F-DCFPyL in Paget’s disease of bone, an important potential pitfall in clinical interpretation of PSMA PET studies. Tomogr J Imaging Res [Internet]. 2015;1:81–4. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4721507&tool=pmcentrez&rendertype=abstract.
  40. 40.
    Sasikumar A, Joy A, Nanabala R, Pillai MR, T. A. H. 68Ga-PSMA PET/CT false-positive tracer uptake in Paget disease. Clin Nucl Med [Internet]. 2016;41:e454–5. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00003072-201610000-00034.CrossRefGoogle Scholar
  41. 41.
    Sasikumar A, Joy A, Pillai MRA, Raman V, Vasudevan A, Madhavan J. A rare case of rectal carcinoma and prostate carcinoma with coexistent Paget’s disease mimicking bone metastases in both 18F-FDG and 68Ga PSMA PET/CT. Eur J Nucl Med Mol Imaging [Internet]. 2017;44:173. Available from: http://link.springer.com/10.1007/s00259-016-3529-8.CrossRefGoogle Scholar
  42. 42.
    De Coster L, Sciot R, Everaerts W, Gheysens O, Verscuren R, Deroose CM, et al. Fibrous dysplasia mimicking bone metastasis on 68GA-PSMA PET/MRI. Eur J Nucl Med Mol Imaging [Internet]. 2017;44:1607–8. Available from: http://link.springer.com/10.1007/s00259-017-3712-6.CrossRefGoogle Scholar
  43. 43.
    Gykiere P, Goethals L, Everaert H. Healing sacral fracture masquerading as metastatic bone disease on a 68Ga-PSMA PET/CT. Clin Nucl Med [Internet]. 2016;41:e346-7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27055135.Google Scholar
  44. 44.
    Vamadevan S, Le K, Bui C, Mansberg R. Incidental PSMA uptake in an undisplaced fracture of a vertebral body. Clin Nucl Med [Internet]. 2017;42:1. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28240660.
  45. 45.
    Sathekge M, Modiselle M, Vorster M, Mokgoro N, Nyakale N, Mokaleng B, et al. 68Ga-PSMA imaging of metastatic breast cancer. Eur J Nucl Med Mol Imaging [Internet]. 2015;42:1482–3. Available from: http://link.springer.com/10.1007/s00259-015-3066-x.CrossRefGoogle Scholar
  46. 46.
    Sathekge M, Lengana T, Modiselle M, Vorster M, Zeevaart JR, Maes A, et al. 68Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients. Eur J Nucl Med Mol Imaging. 2017;44:689–94.PubMedCrossRefGoogle Scholar
  47. 47.
    Denmeade SR, Mhaka AM, Rosen DM, Brennen WN, Dalrymple S, Dach I, et al. Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy. Sci Transl Med [Internet]. 2012;4:140ra86. Available from: http://stm.sciencemag.org/cgi/doi/10.1126/scitranslmed.3003886.Google Scholar
  48. 48.
    Wernicke AG, Varma S, Greenwood EA, Christos PJ, Chao KSC, Liu H, et al. Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancers. APMIS [Internet]. 2014;122:482–9. Available from: http://doi.wiley.com/10.1111/apm.12195.CrossRefGoogle Scholar
  49. 49.
    Malik D, Basher RK, Mittal BR, Jain TK, Bal A, Singh SK. 68Ga-PSMA expression in pseudoangiomatous stromal hyperplasia of the breast. Clin Nucl Med [Internet]. 2017;42:58–60. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00003072-201701000-00014.CrossRefGoogle Scholar
  50. 50.
    Osman MM, Iravani A, Hofman MS, Hicks RJ. Detection of synchronous primary malignancies with 68 Ga-PSMA PET/CT in patients with prostate cancer: frequency in 764 patients. J Nucl Med [Internet]. 2017; Available from: http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.117.190215.
  51. 51.
    Bilgin R, Ergül N, Çermik TF. Incidental meningioma mimicking metastasis of prostate adenocarcinoma in 68Ga-labeled PSMA ligand PET/CT. Clin Nucl Med [Internet]. 2016;41:956–8. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00003072-201612000-00013.CrossRefGoogle Scholar
  52. 52.
    Calabria F, Gangemi V, Gullà D, Schillaci O, Cascini GL. 64 cu-PSMA uptake in meningioma: a potential pitfall of a promising radiotracer. Rev Esp Med Nucl Imagen Mol [Internet]. 2017;36:335–6. Available from: http://linkinghub.elsevier.com/retrieve/pii/S2253654X16300658.Google Scholar
  53. 53.
    Sasikumar A, Joy A, Pillai MRA, Nanabala R, Anees KM, Jayaprakash PG, et al. Diagnostic value of 68Ga PSMA-11 PET/CT imaging of brain tumors-preliminary analysis. Clin Nucl Med [Internet]. 2017;42:e41–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27846000.CrossRefGoogle Scholar
  54. 54.
    Schwenck J, Tabatabai G, Skardelly M, Reischl G, Beschorner R, Pichler B, et al. In vivo visualization of prostate-specific membrane antigen in glioblastoma. Eur J Nucl Med Mol Imaging [Internet]. 2015;42:170–1. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25293865.CrossRefGoogle Scholar
  55. 55.
    Salas Fragomeni RA, Menke JR, Holdhoff M, Ferrigno C, Laterra JJ, Solnes LB, et al. Prostate-specific membrane antigen–targeted imaging with [18F]DCFPyL in high-grade gliomas. Clin Nucl Med [Internet]. 2017;0:1. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28737579%0A, http://Insights.ovid.com/crossref?an=00003072-900000000-97966.
  56. 56.
    Wernicke AG, Edgar MA, Lavi E, Liu H, Salerno P, Bander NH, et al. Prostate-specific membrane antigen as a potential novel vascular target for treatment of glioblastoma multiforme. Arch Pathol Lab Med [Internet]. 2011;135:1486–9. Available from: http://www.archivesofpathology.org/doi/abs/10.5858/arpa.2010-0740-OA.CrossRefGoogle Scholar
  57. 57.
    Noto B, Vrachimis A, Schafers M, Stegger L, Rahbar K. Subacute stroke mimicking cerebral metastasis in 68Ga-PSMA-HBED-CC PET/CT. Clin Nucl Med [Internet]. 2016;41:e449–51. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27355852.CrossRefGoogle Scholar
  58. 58.
    Chan M, Hsiao E. Subacute cortical infarct showing uptake on 68Ga-PSMA PET/CT. Clin Nucl Med [Internet]. 2017;42:110–1. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00003072-201702000-00008.CrossRefGoogle Scholar
  59. 59.
    Šácha P, Zámečník J, Bařinka C, Hlouchová K, Vícha A, Mlčochová P, et al. Expression of glutamate carboxypeptidase II in human brain. Neuroscience. 2007;144:1361–72.PubMedCrossRefGoogle Scholar
  60. 60.
    Godeiro K, de Arantes FA, Antecka E, Odashiro A, Maloney S, Fernandes B, et al. Prostate-specific membrane antigen is undetectable in choroidal neovascular membrane. J Carcinog [Internet]. 2006;5:21. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1560378&tool=pmcentrez&rendertype=abstract.CrossRefGoogle Scholar
  61. 61.
    Wernicke AG, Kim S, Liu H, Bander NH, Pirog EC. Prostate-specific membrane antigen (PSMA) expression in the neovasculature of gynecologic malignancies. Appl Immunohistochem Mol Morphol [Internet]. 2017;25:271–6. Available from: http://insights.ovid.com/crossref?an=00129039-201704000-00007.CrossRefGoogle Scholar
  62. 62.
    Lawhn-Heath C, Flavell RR, Glastonbury C, Hope TA, Behr SC. Incidental detection of head and neck squamous cell carcinoma on 68Ga-PSMA-11 PET/CT. Clin Nucl Med [Internet]. 2017;42:e218–20. Available from: http://insights.ovid.com/crossref?an=00003072-201704000-00038.CrossRefGoogle Scholar
  63. 63.
    Haffner MC, Laimer J, Chaux A, Schäfer G, Obrist P, Brunner A, et al. High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity. Mod Pathol. 2012;25:1079–85.PubMedCrossRefGoogle Scholar
  64. 64.
    Hangaard L, Jochumsen MR, Vendelbo MH, Bouchelouche K. Metastases from colorectal cancer avid on 68Ga-PSMA PET/CT. Clin Nucl Med [Internet]. 2017;42:532–3. Available from: http://insights.ovid.com/crossref?an=00003072-201707000-00007.CrossRefGoogle Scholar
  65. 65.
    Huang Y-TT, Fong W, Thomas P. Rectal carcinoma on 68Ga-PSMA PET/CT. Clin Nucl Med [Internet]. 2016;41:e167–8. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00003072-201603000-00045.CrossRefGoogle Scholar
  66. 66.
    Stoykow C, Huber-Schumacher S, Almanasreh N, Jilg C, Strong RJ, PMSA. Radioligand uptake by rectal carcinoma. Clin Nucl Med [Internet]. 2016;42:1. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00003072-900000000-98245.Google Scholar
  67. 67.
    Abdel-Hadi M, Ismail Y, Younis L. Prostate-specific membrane antigen (PSMA) immunoexpression in the neovasculature of colorectal carcinoma in Egyptian patients. Pathol. Res. Pract. [Internet]. Elsevier GmbH.; 2014;210:759–63. Available from:  https://doi.org/10.1016/j.prp.2014.05.015.
  68. 68.
    Haffner MC, Kronberger IE, Ross JS, Sheehan CE, Zitt M, Mühlmann G, et al. Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Hum. Pathol. [Internet]. Elsevier Inc.; 2009;40:1754–61. Available from:  https://doi.org/10.1016/j.humpath.2009.06.003.
  69. 69.
    Demirci E, Ocak M, Kabasakal L, Decristoforo C, Talat Z, Halaç M, et al. 68Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging [Internet]. 2014;41:1461–2. Available from: http://link.springer.com/10.1007/s00259-014-2766-y.CrossRefGoogle Scholar
  70. 70.
    Gorin MA, Rowe SP, Hooper JE, Kates M, Hammers HJ, Szabo Z, et al. PSMA-targeted 18F-DCFPyL PET/CT imaging of clear cell renal cell carcinoma: results from a rapid autopsy. Eur Urol [Internet]. 2016;71:18–9. Available from:  https://doi.org/10.1016/j.eururo.2016.06.019.
  71. 71.
    Rhee H, Ng KL, Tse BW-C, Yeh M-C, Russell PJ, Nelson C, et al. Using prostate-specific membrane antigen (PSMA) expression in clear cell renal cell carcinoma for imaging advanced disease. Pathology [Internet]. 2016;48:613–6. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0031302516397616.Google Scholar
  72. 72.
    Rowe SP, Gorin MA, Hammers HJ, Pomper MG, Allaf ME, Javadi MS. Detection of 18F-FDG PET/CT occult lesions with 18F-DCFPyL PET/CT in a patient with metastatic renal cell carcinoma. Clin Nucl Med [Internet]. 2016;41:83–5. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26402128.
  73. 73.
    Sasikumar A, Joy A, Nanabala R, Unni M, TK P. Complimentary pattern of uptake in 18F-FDG PET/CT and 68Ga–prostate-specific membrane antigen PET/CT in a case of metastatic clear cell renal carcinoma. Clin Nucl Med [Internet]. 2016;41:e517–9. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00003072-201612000-00036.CrossRefGoogle Scholar
  74. 74.
    Zacho HD, Nielsen JB, Dettmann K, Haberkorn U, Petersen LJ. Incidental detection of thyroid metastases from renal cell carcinoma using 68Ga-PSMA PET/CT to assess prostate cancer recurrence. Clin Nucl Med [Internet]. 2016;42:1. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00003072-900000000-98224.Google Scholar
  75. 75.
    Joshi A, Nicholson C, Rhee H, Gustafson S, Miles K, Vela I. Incidental malignancies identified during staging for prostate cancer with 68 Ga -PSMA HBED-CC PET imaging. Urology [Internet]. Elsevier Inc.; 2017;104:e3–4. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0090429517302716.
  76. 76.
    Nadebaum DP, Hofman MS, Mitchell CA, Siva S, Hicks RJ. Oligometastatic renal cell carcinoma with sarcomatoid differentiation demonstrating variable imaging phenotypes on 68Ga-PSMA and 18F–FDG PET/CT: a case report and review of the literature. Clin Genitourin Cancer [Internet]. Elsevier Inc.; 2017;1–5. Available from:  https://doi.org/10.1016/j.clgc.2017.08.009.
  77. 77.
    Rhee H, Blazak J, Tham CM, Ng KL, Shepherd B, Lawson M, et al. Pilot study: use of gallium-68 PSMA PET for detection of metastatic lesions in patients with renal tumour. EJNMMI Res [Internet]. 2016;6:76. Available from: http://ejnmmires.springeropen.com/articles/10.1186/s13550-016-0231-6.CrossRefGoogle Scholar
  78. 78.
    Rowe SP, Gorin MA, Hammers HJ, Som Javadi M, Hawasli H, Szabo Z, et al. Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT. Ann Nucl Med Springer Japan. 2015;29:877–82.CrossRefGoogle Scholar
  79. 79.
    Siva S, Callahan J, Pryor D, Martin J, Lawrentschuk N, Hofman MS. Utility of 68 Ga prostate-specific membrane antigen - positron emission tomography in diagnosis and response assessment of recurrent renal cell carcinoma. J Med Imaging Radiat Oncol [Internet]. 2017;61:372–8. Available from: http://doi.wiley.com/10.1111/1754-9485.12590.CrossRefGoogle Scholar
  80. 80.
    Sawicki LM, Buchbender C, Boos J, Giessing M, Ermert J, Antke C, et al. Diagnostic potential of PET/CT using a 68Ga-labelled prostate-specific membrane antigen ligand in whole-body staging of renal cell carcinoma: initial experience. Eur J Nucl Med Mol Imaging [Internet]. 2017;44:102–7. Available from: http://dx.doi.org/10.1007/s00259-016-3360-2.CrossRefGoogle Scholar
  81. 81.
    Chang SS, Reuter VE, Heston WD, Gaudin PB. Metastatic renal cell carcinoma neovasculature expresses prostate-specific membrane antigen. Urology [Internet]. 2001;57:801–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11306418.CrossRefGoogle Scholar
  82. 82.
    Baccala A, Sercia L, Li J, Heston W, Zhou M. Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms. Urology. 2007;70:385–90.PubMedCrossRefGoogle Scholar
  83. 83.
    Al-Ahmadie HA, Olgac S, Gregor PD, Tickoo SK, Fine SW, Kondagunta GV, et al. Expression of prostate-specific membrane antigen in renal cortical tumors. Mod Pathol. 2008;21:727–32.PubMedCrossRefGoogle Scholar
  84. 84.
    Spatz S, Tolkach Y, Jung K, Stephan C, Busch J, Ralla B, et al. Comprehensive evaluation of prostate-specific membrane antigen expression in the vasculature of renal tumors: implications for imaging studies and prognostic role. J Urol [Internet]. 2017; Available from: http://linkinghub.elsevier.com/retrieve/pii/S0022534717773764.
  85. 85.
    Einspieler I, Tauber R, Maurer T, Schwaiger M, Eiber M. 68Ga prostate-specific membrane antigen uptake in renal cell cancer lymph node metastases. Clin Nucl Med [Internet]. 2016;41:e261–2. Available from: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=prem&NEWS=N&AN=26859205.CrossRefGoogle Scholar
  86. 86.
    Sasikumar A, Joy A, Nanabala R, Pillai MRA, Thomas B, Vikraman KR. 68Ga-PSMA PET/CT imaging in primary hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2016;43:795–6.PubMedCrossRefGoogle Scholar
  87. 87.
    Soydal C, Alkan A, Ozkan E, Demirkazik A, Kucuk N. Ga-68 PSMA accumulation in hepatocellular carcinoma. Clin. Oncol. 2016;1.Google Scholar
  88. 88.
    Taneja S, Taneja R, Kashyap V, Jha A, Jena A. 68Ga-PSMA uptake in hepatocellular carcinoma. Clin Nucl Med [Internet]. 2017;42:e69–70. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00003072-201701000-00039.CrossRefGoogle Scholar
  89. 89.
    Shetty D, Loh H, Bui C, Mansberg R, Stevanovic A. Elevated 68Ga prostate-specific membrane antigen activity in metastatic non–small cell lung cancer. Clin Nucl Med [Internet]. 2016;41:414–6. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00003072-201605000-00022.CrossRefGoogle Scholar
  90. 90.
    Pyka T, Weirich G, Einspieler I, Maurer T, Theisen J, Hatzichristodoulou G, et al. 68Ga-PSMA-HBED-CC PET for differential diagnosis of suggestive lung lesions in patients with prostate cancer. J Nucl Med [Internet]. 2016;57:367–71. Available from: http://jnm.snmjournals.org/cgi/doi/10.2967/jnumed.115.164442.CrossRefGoogle Scholar
  91. 91.
    Wang H, Wang S, Song W, Pan Y, Yu H, Si T, et al. Expression of prostate-specific membrane antigen in lung cancer cells and tumor Neovasculature endothelial cells and its clinical significance. PLoS One [Internet]. 2015;10:e0125924. Available from: http://dx.plos.org/10.1371/journal.pone.0125924.CrossRefGoogle Scholar
  92. 92.
    Bouchelouche K, Vendelbo MH. Pulmonary opacities and bronchiectasis avid on 68Ga-PSMA PET. Clin Nucl Med [Internet]. 2017;42:e216–7. Available from: http://insights.ovid.com/crossref?an=00003072-201704000-00037.CrossRefGoogle Scholar
  93. 93.
    Ardies PJ, Gykiere P, Goethals L, De Mey J, De Geeter F, Everaert H. PSMA uptake in mediastinal sarcoidosis. Clin Nucl Med [Internet]. 2017;42:1. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00003072-900000000-98191.CrossRefGoogle Scholar
  94. 94.
    Dias AH, Holm Vendelbo M, Bouchelouche K. Uptake in lymph nodes with active sarcoidosis. Clin Nucl Med [Internet]. 2016;42:1. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00003072-900000000-98216.Google Scholar
  95. 95.
    Elri T, Aras M, Salihoglu YS, Erdemir RU, Cabuk M. A potential pitfall in the use of (68)Ga-PSMA PET/CT. Anthracosis Rev Esp Med Nucl Imagen Mol [Internet]. Elsevier España, S.L.U. and SEMNIM; 2016;36:65–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27666999.
  96. 96.
    Kanthan GL, Coyle L, Kneebone A, Schembri GP, Hsiao E. Follicular lymphoma showing avid uptake on 68Ga PSMA-HBED-CC PET/CT. Clin Nucl Med [Internet]. 2016;41:500–1. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00003072-201606000-00023.CrossRefGoogle Scholar
  97. 97.
    Vamadevan S, Le K, Bui C, Mansberg R. Prostate-specific membrane antigen uptake in small cleaved B-cell follicular non-Hodgkin lymphoma. Clin Nucl Med [Internet]. 2016;41:980–1. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27749416.CrossRefGoogle Scholar
  98. 98.
    Rauscher I, Maurer T, Steiger K, Schwaiger M, Eiber M. Multifocal 68Ga prostate-specific membrane antigen ligand uptake in the skeleton in a man with both prostate cancer and multiple myeloma. Clin Nucl Med [Internet]. 2017;42:547–8. Available from: http://insights.ovid.com/crossref?an=00003072-900000000-98078.CrossRefGoogle Scholar
  99. 99.
    Sasikumar A, Joy A, Pillai MRA, Nanabala R, Thomas B. 68Ga-PSMA PET/CT imaging in multiple myeloma. Clin Nucl Med [Internet]. 2017;42:e126–7. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00003072-201702000-00040.CrossRefGoogle Scholar
  100. 100.
    Froehner M, Kuithan F, Zöphel K, Heberling U, Laniado M, Wirth MP. Prostate-specific membrane antigen-targeted ligand positron emission tomography/computed tomography and immunohistochemical findings in a patient with synchronous metastatic penile and prostate cancer. Urology [Internet]. Elsevier Inc.; 2017;101:e5–6. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0090429516309232.
  101. 101.
    Stephens M, Kim DI, Shepherd B, Gustafson S, Thomas P. Intense uptake in amyloidosis of the seminal vesicles on 68Ga-PSMA PET mimicking locally advanced prostate cancer. Clin Nucl Med [Internet]. 2017;42:147–8. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00003072-201702000-00025.CrossRefGoogle Scholar
  102. 102.
    Ren H, Zhang H, Wang X, Liu J, Yuan Z, Hao J. Prostate-specific membrane antigen as a marker of pancreatic cancer cells. Med Oncol [Internet]. 2014;31:–857. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24477651
  103. 103.
    Chan M, Schembri GP, Hsiao E. Serous cystadenoma of the pancreas showing uptake on 68Ga PSMA PET/CT. Clin Nucl Med. 2017;42:56–7.PubMedCrossRefGoogle Scholar
  104. 104.
    Vamadevan S, Shetty D, Le K, Bui C, Mansberg R, Loh H. Prostate-Specific Membrane Antigen (PSMA) avid pancreatic neuroendocrine tumor. Clin Nucl Med [Internet]. 2016;41:804–6. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00003072-201610000-00019.
  105. 105.
    Kanthan GL, Izard MA, Emmett L, Hsiao E, Schembri GP. Schwannoma showing avid uptake on 68Ga-PSMA-HBED-CC PET/CT. Clin Nucl Med [Internet]. 2016;41:703–4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27405039.CrossRefGoogle Scholar
  106. 106.
    Rischpler C, Maurer T, Schwaiger M, Eiber M. Intense PSMA-expression using 68Ga-PSMA PET/CT in a paravertebral schwannoma mimicking prostate cancer metastasis. Eur J Nucl Med Mol Imaging. 2016;43:193–4.PubMedCrossRefGoogle Scholar
  107. 107.
    Wang W, Tavora F, Sharma R, Eisenberger M, Netto GJ. PSMA expression in Schwannoma: A potential clinical mimicker of metastatic prostate carcinoma. Urol. Oncol. Semin. Orig. Investig. [Internet]. Elsevier Inc.; 2009;27:525–8. Available from:  https://doi.org/10.1016/j.urolonc.2008.04.007.
  108. 108.
    Vamadevan S, Le K, Shen L, Ha L, Mansberg R. Incidental prostate-specific membrane antigen uptake in a peripheral nerve sheath tumor. Clin Nucl Med [Internet]. 2017;42:560–2. Available from: http://insights.ovid.com/crossref?an=00003072-201707000-00019.CrossRefGoogle Scholar
  109. 109.
    Derlin T, Schumacher U, Bengel FM. Nonneoplastic neuroma after radical prostatectomy is not a mimicker of lymph node metastases on 68Ga–PSMA ligand PET/CT. Clin Nucl Med [Internet]. 2016;41:785–6. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00003072-201610000-00011.CrossRefGoogle Scholar
  110. 110.
    Beheshti M, Rezaee A, Langsteger W. 68Ga-PSMA-HBED uptake on cervicothoracic (stellate) ganglia, a common pitfall on PET/CT. Clin Nucl Med [Internet]. 2016;42:1. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00003072-900000000-98220.Google Scholar
  111. 111.
    Krohn T, Verburg FA, Pufe T, Neuhuber W, Vogg A, Heinzel A, et al. [68Ga]PSMA-HBED uptake mimicking lymph node metastasis in coeliac ganglia: an important pitfall in clinical practice. Eur J Nucl Med Mol Imaging [Internet]. 2015;42:210–4. Available from: http://link.springer.com/10.1007/s00259-014-2915-3.CrossRefGoogle Scholar
  112. 112.
    Kanthan GL, Hsiao E, Vu D, Schembri GP. Uptake in sympathetic ganglia on 68 Ga-PSMA-HBED PET/CT: A potential pitfall in scan interpretation. J. Med. Imaging Radiat. Oncol. [Internet]. 2017;1–7. Available from: http://doi.wiley.com/10.1111/1754-9485.12622.
  113. 113.
    Lütje S, Sauerwein W, Lauenstein T, Bockisch A, Poeppel TD. In vivo visualization of prostate-specific membrane antigen in adenoid cystic carcinoma of the salivary gland. Clin Nucl Med [Internet]. 2016;41:476–7. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00003072-201606000-00013.CrossRefGoogle Scholar
  114. 114.
    de Keizer B, Krijger GC, Ververs FT, van Es RJJ, de Bree R, Willems S. 68Ga-PSMA PET-CT imaging of metastatic adenoid cystic carcinoma. Nucl Med Mol Imaging [Internet]. Nuclear Medicine and Molecular Imaging. 2017;51:360–361. Available from:  https://doi.org/10.1007/s13139-016-0445-6.
  115. 115.
    Klein Nulent TJW, van Es RJJ, Krijger GC, de Bree R, Willems SM, de Keizer B. Prostate-specific membrane antigen PET imaging and immunohistochemistry in adenoid cystic carcinoma-a preliminary analysis. Eur J Nucl Med Mol Imaging [Internet]. 2017; Available from: http://link.springer.com/10.1007/s00259-017-3737-x.
  116. 116.
    Wolf P, Freudenberg N, Bühler P, Alt K, Schultze-Seemann W, Wetterauer U, et al. Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer. Prostate. 2010;70:562–9.PubMedGoogle Scholar
  117. 117.
    Aydin F, Akçal A, Ünal B, Sezgin Göksu S, Güngör F. 68Ga-PSMA uptake by dermatofibroma in a patient with prostate cancer. Clin Nucl Med [Internet]. 2017;42:358–60. Available from: http://insights.ovid.com/crossref?an=00003072-201705000-00007.CrossRefGoogle Scholar
  118. 118.
    Daglioz Gorur G, Hekimsoy T, Isgoren S, Sikar Akturk A, Demir H. Uptake of an Acrochordon incidentally detected on 68Ga prostate-specific membrane antigen PET/CT. Clin Nucl Med [Internet]. 2017;42:461–2. Available from: http://insights.ovid.com/crossref?an=00003072-201706000-00012.CrossRefGoogle Scholar
  119. 119.
    Kobe C, Maintz D, Fischer T, Drzezga A, Chang D-H. Prostate-specific membrane antigen PET/CT in splenic sarcoidosis. Clin Nucl Med [Internet]. 2015;40:897–8. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00003072-201511000-00017.CrossRefGoogle Scholar
  120. 120.
    Kanthan GL, Hsiao E, Kneebone A, Eade T, Schembri GP. Desmoid tumor showing intense uptake on 68Ga PSMA-HBED-CC PET/CT. Clin Nucl Med [Internet]. 2016;41:508–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26909712.CrossRefGoogle Scholar
  121. 121.
    Noto B, Weckesser M, Buerke B, Pixberg M, Avramovic N. Gastrointestinal stromal tumor showing intense tracer uptake on PSMA PET/CT. Clin Nucl Med [Internet]. 2017;42:1. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00003072-900000000-98200.CrossRefGoogle Scholar
  122. 122.
    Zacho HD, Nielsen JB, Dettmann K, Hjulskov SHPL. 68Ga-PSMA PET/CT uptake in intramuscular myxoma imitates prostate cancer metastasis. Clin Nucl Med. 2017;42:487–8.Google Scholar
  123. 123.
    Henninger M, Maurer T, Hacker C, Eiber M. 68Ga-PSMA PET/MR showing intense PSMA uptake in nodular fasciitis mimicking prostate cancer metastasis. Clin Nucl Med [Internet]. 2016;41:e443–4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27488427.CrossRefGoogle Scholar
  124. 124.
    Huang HL, Dharmawan AR, Tan CJ, Thang SP. A rare case of thymoma first detected on gallium-68 PSMA PET/CT. Eur J Nucl Med Mol Imaging [Internet]. 2017:1–2. Available from: http://link.springer.com/10.1007/s00259-017-3785-2.
  125. 125.
    Taywade SK, Damle NA, Bal C. PSMA expression in papillary thyroid carcinoma. Clin Nucl Med [Internet]. 2016;41:e263–5. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00003072-201605000-00040.CrossRefGoogle Scholar
  126. 126.
    Sager S, Vatankulu B, Uslu L, Sonmezoglu K. Incidental detection of follicular thyroid carcinoma in 68Ga-PSMA PET/CT imaging. J Nucl Med Technol [Internet]. 2016;44:199–200. Available from: http://tech.snmjournals.org/cgi/doi/10.2967/jnmt.115.171660.CrossRefGoogle Scholar
  127. 127.
    Lütje S, Gomez B, Cohnen J, Umutlu L, Gotthardt M, Poeppel TD, et al. Imaging of prostate-specific membrane antigen expression in metastatic differentiated thyroid cancer using 68Ga-HBED-CC-PSMA PET/CT. Clin Nucl Med [Internet]. 2017;42:20–5. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00003072-201701000-00004.CrossRefGoogle Scholar
  128. 128.
    Bychkov A, Vutrapongwatana U, Tepmongkol S, Keelawat S. PSMA expression by microvasculature of thyroid tumors – Potential implications for PSMA theranostics. Sci. Rep. [Internet]. Springer US; 2017;7:5202. Available from: http://www.nature.com/articles/s41598-017-05481-z.
  129. 129.
    Verburg FA, Krohn T, Heinzel A, Mottaghy FM, Behrendt FF. First evidence of PSMA expression in differentiated thyroid cancer using [68Ga]PSMA-HBED-CC PET/CT. Eur J Nucl Med Mol Imaging. 2015;42:1622–3.PubMedCrossRefGoogle Scholar
  130. 130.
    Damle NA, Tripathi M, Chakraborty PS, Sahoo MK, Bal C, Aggarwal S, et al. Unusual uptake of prostate-specific tracer 68Ga-PSMA–HBED-CC in a Benign Thyroid Nodule. Nucl. Med. Mol. Imaging (2010). [Internet]. 2016;50:344–7. Available from: http://link.springer.com/10.1007/s13139-016-0408-y.
  131. 131.
    Derlin T, Kreipe H-H, Schumacher U, Soudah B. PSMA expression in tumor Neovasculature endothelial cells of follicular thyroid adenoma as identified by molecular imaging using 68Ga-PSMA ligand PET/CT. Clin Nucl Med [Internet]. 2016;42:1. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00003072-900000000-98244.Google Scholar
  132. 132.
    Kanthan GL, Drummond J, Schembri GP, Izard MA, Hsiao E. Follicular thyroid adenoma showing avid uptake on 68Ga PSMA-HBED-CC PET/CT. Clin Nucl Med [Internet]. 2016;41:331–2. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00003072-201604000-00018.CrossRefGoogle Scholar
  133. 133.
    Gupta M, Choudhury P, Gupta G, Gandhi J. Metastasis in urothelial carcinoma mimicking prostate cancer metastasis in Ga-68 prostate-specific membrane antigen positron emission tomography-computed tomography in a case of synchronous malignancy. Indian J Nucl Med [Internet]. 2016;31:222. Available from: http://www.ijnm.in/text.asp?2016/31/3/222/183615.CrossRefGoogle Scholar
  134. 134.
    Roy SG, Parida GK, Tripathy S, Singhal A, Tripathi M, Bal C. In vivo demonstration of PSMA expression in adenocarcinoma urinary bladder using 68Ga-PSMA 11 PET/CT. Clin Nucl Med [Internet]. 2017;42:542–3. Available from: http://insights.ovid.com/crossref?an=00003072-201707000-00011.CrossRefGoogle Scholar
  135. 135.
    Samplaski MK, Heston W, Elson P, Magi-Galluzzi C, Hansel DE. Folate hydrolase (prostate-specific antigen) 1 expression in bladder cancer subtypes and associated tumor neovasculature. Mod. Pathol. [Internet]. Nature Publishing Group; 2011;24:1521–9. Available from: http://www.nature.com/doifinder/10.1038/modpathol.2011.112.
  136. 136.
    Artigas C, Otte F-X, Lemort M, van Velthoven R, Flamen P. Vertebral hemangioma mimicking bone metastasis in 68Ga—PSMA ligand PET/CT. Clin Nucl Med [Internet]. 2017;42:368–70. Available from: http://insights.ovid.com/crossref?an=00003072-201705000-00010.CrossRefGoogle Scholar
  137. 137.
    Probst S, Bladou F, Abikhzer G. Extraosseous extension of aggressive vertebral hemangioma as a potential pitfall on 68Ga-PSMA PET/CT. Clin Nucl Med [Internet]. 2017;42:1. Available from: http://insights.ovid.com/crossref?an=00003072-900000000-97999.CrossRefGoogle Scholar
  138. 138.
    Bhardwaj H, Stephens M, Bhatt M, Thomas PA. Prostate-specific membrane antigen PET/CT findings for hepatic hemangioma. Clin Nucl Med [Internet]. 2016;41:968–9. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00003072-201612000-00018.CrossRefGoogle Scholar
  139. 139.
    Jochumsen MR, Vendelbo MH, Høyer S, Bouchelouche K. Subcutaneous lobular capillary hemangioma on 68Ga-PSMA PET/CT. Clin Nucl Med [Internet]. 2017;42:e214–5. Available from: http://insights.ovid.com/crossref?an=00003072-201704000-00036.CrossRefGoogle Scholar
  140. 140.
    Derlin T, Baumann U, Bengel FM. Molecular imaging of glutamate-carboxypeptidase II (prostate-specific membrane antigen) in malignant epithelioid hemangioendothelioma. Eur J Nucl Med Mol Imaging. 2015;42:1943–4.PubMedCrossRefGoogle Scholar
  141. 141.
    Derlin T, Thiele J, Weiberg D, Thackeray JT, Püschel K, Wester H-J, et al. Evaluation of 68 Ga-glutamate carboxypeptidase II ligand positron emission tomography for clinical molecular imaging of atherosclerotic plaque neovascularization highlights. Arterioscler Thromb Vasc Biol [Internet]. 2016;36:2213–9. Available from: http://atvb.ahajournals.org/lookup/doi/10.1161/ATVBAHA.116.307701.CrossRefGoogle Scholar
  142. 142.
    Milowsky MI, Nanus DM, Kostakoglu L, Sheehan CE, Vallabhajosula S, Goldsmith SJ, et al. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol. 2007;25:540–7.PubMedCrossRefGoogle Scholar
  143. 143.
    Pandit-Taskar N, O’Donoghue JA, Divgi CR, Wills EA, Schwartz L, Gönen M, et al. Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors. EJNMMI Res [Internet]. 2015;5:28. Available from: http://www.ejnmmires.com/content/5/1/28.CrossRefGoogle Scholar
  144. 144.
    Mhawech-Fauceglia P, Zhang S, Terracciano L, Sauter G, Chadhuri A, Herrmann FR, et al. Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique. Histopathology. 2007;50:472–83.PubMedCrossRefGoogle Scholar
  145. 145.
    Gala JL, Loric S, Guiot Y, Denmeade SR, Gady A, Brasseur F, et al. Expression of prostate-specific membrane antigen in transitional cell carcinoma of the bladder: prognostic value? Clin Cancer Res [Internet]. 2000;6:4049–54. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11051255.Google Scholar
  146. 146.
    Loh J, Davis ID, Martin JM, Siva S. Extracranial oligometastatic renal cell carcinoma: current management and future directions. Futur Oncol [Internet]. 2014;10:761–74. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L373029807%5Cn ,  https://doi.org/10.2217/fon.14.40%5Cn , http://bj7rx7bn7b.search.serialssolutions.com?sid=EMBASE&issn=17448301&id=doi:10.2217%2Ffon.14.40&atitle=Extracranial+oligometast.
  147. 147.
    Cairns P. Renal cell carcinoma. Srivastava S, Grizzle WE, editors. Cancer Biomarkers [Internet]. 2011;9:461–73. Available from: http://www.medra.org/servlet/aliasResolver?alias=iospress&doi=10.3233/CBM-2011-0176.
  148. 148.
    Jayson GC, Kerbel R, Ellis LM, Harris AL. Antiangiogenic therapy in oncology: current status and future directions. Lancet (London, England) [Internet]. Elsevier Ltd; 2016;388:518–529. Available from:  https://doi.org/10.1016/S0140-6736(15)01088-0.
  149. 149.
    Conway RE, Petrovic N, Li Z, Heston W, Wu D, Shapiro LH. Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Mol Cell Biol [Internet]. 2006;26:5310–24. Available from: http://mcb.asm.org/cgi/doi/10.1128/MCB.00084-06.CrossRefGoogle Scholar
  150. 150.
    Conway RE, Joiner K, Patterson A, Bourgeois D, Rampp R, Hannah BC, et al. Prostate-specific membrane antigen produces pro-angiogenic laminin peptides downstream of matrix metalloprotease-2. Angiogenesis. 2013;16:847–60.PubMedCrossRefGoogle Scholar
  151. 151.
    Conway RE, Rojas C, Alt J, Nováková Z, Richardson SM, Rodrick TC, et al. Prostate-specific membrane antigen (PSMA)-mediated laminin proteolysis generates a pro-angiogenic peptide. Angiogenesis. 2016;19:487–500.PubMedCrossRefGoogle Scholar
  152. 152.
    Ferrara N. Microvascular density as a predictive biomarker for bevacizumab survival benefit in ovarian cancer: back to first principles? JNCI J Natl Cancer Inst [Internet]. 2017;109:14–5. Available from: https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/djx067.Google Scholar
  153. 153.
    Bais C, Mueller B, Brady MF, Mannel RS, Burger RA, Wei W, et al. Tumor microvessel density as a potential predictive marker for bevacizumab benefit: GOG-0218 biomarker analyses. JNCI J Natl Cancer Inst [Internet]. 2017;109:1–10. Available from: https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/djx066.Google Scholar
  154. 154.
    O’Connor JPB, Jayson GC. Do imaging biomarkers relate to outcome in patients treated with VEGF inhibitors? Clin Cancer Res. 2012;18:6588–98.PubMedCrossRefGoogle Scholar
  155. 155.
    Beer AJ, Dijkgraaf I. Editorial European Journal of Nuclear Medicine and Molecular Imaging. Eur J Nucl Med Mol Imaging [Internet]; 2017;44:284–5. Available from:  https://doi.org/10.1007/s00259-016-3559-2.
  156. 156.
    Hong H, Chen F, Zhang Y, Cai W. New radiotracers for imaging of vascular targets in angiogenesis-related diseases. Adv. Drug Deliv. Rev. [Internet]. Elsevier B.V.; 2014;76:2–20. Available from:  https://doi.org/10.1016/j.addr.2014.07.011.
  157. 157.
    Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A, et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European network for the study of adrenal tumors. Eur J Endocrinol. 2016;175:G1–34.PubMedCrossRefGoogle Scholar
  158. 158.
    Ansquer C, Scigliano S, Mirallié E, Taïeb D, Brunaud L, Sebag F, et al. 18F-FDG PET/CT in the characterization and surgical decision concerning adrenal masses: a prospective multicentre evaluation. Eur J Nucl Med Mol Imaging. 2010;37:1669–78.PubMedCrossRefGoogle Scholar
  159. 159.
    Bubendorf L, Schöpfer A, Wagner U, Sauter G, Moch H, Willi N, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol [Internet]. 2000;31:578–83. Available from: http://www.sciencedirect.com/science/article/pii/S0046817700800350.CrossRefGoogle Scholar
  160. 160.
    Chakraborty PS, Kumar R, Tripathi M, Das CJ, Bal C. Detection of brain metastasis with 68Ga-labeled PSMA ligand PET/CT: a novel radiotracer for imaging of prostate carcinoma. Clin Nucl Med [Internet]. 2015;40:328–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25674861.CrossRefGoogle Scholar
  161. 161.
    Ha D, Bing SJ, Ahn G, Kim J, Cho J, Kim A, et al. Blocking glutamate carboxypeptidase II inhibits glutamate excitotoxicity and regulates immune responses in experimental autoimmune encephalomyelitis. FEBS J. 2016;283:3438–56.PubMedCrossRefGoogle Scholar
  162. 162.
    Lee J, Baird A, Eliceiri BP. Vascular Normalization. In: Milner R, editor. Cerebral Angiogenesis: Friend or Foe? [Internet]. Springer New York: New York; 2014. Available from: http://link.springer.com/10.1007/978-1-4939-0320-7.Google Scholar
  163. 163.
    Emmett L, Willowson K, Violet J, Shin J, Blanksby A, Lee J. Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy. J Med Radiat Sci. 2017;64:52–60.PubMedPubMedCentralCrossRefGoogle Scholar
  164. 164.
    Fendler WP, Kratochwil C, Ahmadzadehfar H, Rahbar K, Baum RP, Schmidt M, et al. 177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer. Nuklearmedizin [Internet]. 2016;55:123–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27350005.Google Scholar
  165. 165.
    Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schäfers M, Essler M, et al. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med [Internet]. 2017;58:85–90. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27765862.CrossRefGoogle Scholar
  166. 166.
    Ahmadzadehfar H, Eppard E, Kurpig S, Fimmers R, Yordanova A, Schlenkhoff CD, et al. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget. 2016;7:12477–88.PubMedPubMedCentralCrossRefGoogle Scholar
  167. 167.
    Ahmadzadehfar H, Rahbar K, Kürpig S, Bögemann M, Claesener M, Eppard E, et al. Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI Res [Internet]. 2015;5:114. Available from: http://ejnmmires.springeropen.com/articles/10.1186/s13550-015-0114-2.Google Scholar
  168. 168.
    Rahbar K, Schmidt M, Heinzel A, Eppard E, Bode A, Yordanova A, et al. Response and tolerability of a single dose of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: a multicenter retrospective analysis. J Nucl Med [Internet]. 2016;57:1334–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27056618.CrossRefGoogle Scholar
  169. 169.
    Rahbar K, Bode A, Weckesser M, Avramovic N, Claesener M, Stegger L, et al. Radioligand therapy with 177Lu-PSMA-617 as a novel therapeutic option in patients with metastatic castration-resistant prostate cancer. Clin Nucl Med [Internet]. 2016;41:522–8. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27088387.
  170. 170.
    Dash A, Pillai MRA, Knapp FF. Production of 177Lu for targeted radionuclide therapy: available options. Nucl Med Mol Imaging (2010). 2015;49:85–107.Google Scholar
  171. 171.
    Kratochwil C, Bruchertseifer F, Giesel FL, Weis M, Verburg FA, Mottaghy F, et al. 225Ac-PSMA-617 for PSMA-targeted radiation therapy of metastatic castration-resistant prostate cancer. J Nucl Med [Internet]. 2016;57:1941–4. Available from: http://jnm.snmjournals.org/cgi/doi/10.2967/jnumed.116.178673.CrossRefGoogle Scholar
  172. 172.
    Sgouros G, Roeske JC, McDevitt MR, Palm S, Allen BJ, Fisher DR, et al. MIRD pamphlet no. 22: radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med. 2010;51:311–28.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Philipp Backhaus
    • 1
    • 2
  • Benjamin Noto
    • 1
  • Nemanja Avramovic
    • 1
  • Lena Sophie Grubert
    • 1
  • Sebastian Huss
    • 3
  • Martin Bögemann
    • 4
  • Lars Stegger
    • 1
  • Matthias Weckesser
    • 1
  • Michael Schäfers
    • 1
    • 2
  • Kambiz Rahbar
    • 1
  1. 1.Department of Nuclear MedicineUniversity Hospital MünsterMünsterGermany
  2. 2.European Institute for Molecular imaging (EIMI), University of MünsterMünsterGermany
  3. 3.Gerhard Domagk Institute for PathologyUniversity Hospital of MünsterMünsterGermany
  4. 4.Department of UrologyUniversity Hospital MünsterMünsterGermany

Personalised recommendations